Quick Facts at a Glance
- Recall Date
- February 10, 2026
- Hazard Level
- HIGH
- Brands
- ADBRY, LEO Pharma Inc.
- Category
- Health & Personal Care
- Sold At
- Multiple Retailers
- Geographic Scope
- 1 states
- At-Risk Groups
- GENERAL
What to Do Now
Use this page like a recall checklist: verify the product first, then act on the official remedy.
Immediate steps
- 1Stop using the product until you confirm whether it is included in the recall.
- 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
- 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
- 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.
Check these identifiers
- Brand
- ADBRY, LEO Pharma Inc.
- Product type
- Injection
- Model numbers
- Lot: a) 003E24C, Exp 04/30/2027, b) 003E24A, Exp 04/30/2027.
- UPC codes
- 50222-346, 50222-350, 50222-346-01, 50222-346-02, 50222-346-22, 50222-346-04, 50222-346-91, 50222-346-92 +4 more
- Sold at
- Multiple Retailers
- Where affected
- ALL
Recall Timeline
Key dates and source checks for this recall record.
Recall announced
February 10, 2026
Reported by FDA DRUG
March 4, 2026
RecallRadar source check
March 11, 2026
Consumer action
Use the official remedy and keep documentation.
Hazard Information
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact LEO PHARMA INC or your healthcare provider for guidance. Notification method: E-Mail
About This Product
Adbry is an injection used primarily for the treatment of eczema. Patients often purchase this medication because it is effective in managing symptoms and providing relief.
Why This Is Dangerous
The presence of wool fiber in the injection raises serious concerns about sterility and potential contamination, which can lead to infections or other health issues.
Industry Context
This recall is not part of a broader industry pattern.
Real-World Impact
Consumers must stop using the product immediately, as continued use could pose serious health risks due to potential contamination.
Practical Guidance
How to identify if yours is affected
- Locate the lot number on your Adbry injection packaging.
- Check if it matches the recalled lot numbers: a) 003E24C or b) 003E24A.
- Verify the expiration date is 04/30/2027.
Where to find product info
The lot number can be found on the packaging of the product, usually near the expiration date or barcode.
What timeline to expect
Expect a refund processing timeline of 4-6 weeks after contacting LEO Pharma Inc.
If the manufacturer is unresponsive
- Document all communication attempts with LEO Pharma Inc.
- Consider filing a complaint with the FDA if no response is received.
How to prevent similar issues
- Always check for recalls before purchasing medications.
- Consult healthcare providers for the latest safety information on medications.
- Be aware of any changes in product appearance or packaging.
Documentation advice
Keep records of your purchase, including receipts and correspondence with the manufacturer.
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Product Details
The recall includes Adbry injection, 300 mg/2mL, packaged as 1 x Single dose Autoinjector (NDC 50222-350-91) and 2 x Single dose Autoinjectors (NDC 50222-350-02). The product was distributed nationwide in the USA.
Key Facts
- Recall date: February 10, 2026
- Reported date: March 4, 2026
- Quantity recalled: 11,407 units
- Class II recall
- Manufactured by LEO Pharma A/S, Denmark
Browse More Recalls
Safety Guide
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet Alerts for Health & Personal Care Recalls
Get instant alerts for recalls that affect you. Free forever.
